Registry-embedded randomisation of treatment order in routine care
When two approved drugs are both reasonable next steps and nobody knows which should come first, let the clinic flip a coin and record what happens.
Point-of-care randomisation embedded in the electronic record (as in the TASTE trial in cardiology and the NHS PRINCIPLE platform) can answer sequencing questions about approved drugs with thousands of patients at low cost. Consent is simplified because both options are standard of care; follow-up uses routine data.
- Too many combinations to test · There are thousands of possible drug pairs and sequences. Trials can test a few dozen a year.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
Pages like this
not linked directly; found by shared links- IdeaRecord what happens when doctors use cancer drugs off-label
Shares Payers cover off-label combinations only inside registry-randomised trials, Weak real-world evidence and registries, Real-world evidence.
- IdeaA real-world sequencing analysis within a year of every new approval
Shares ADC sequencing, Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.
- IdeaPay for new biomarker tests only while evidence of clinical utility is being collected
Shares Payers cover off-label combinations only inside registry-randomised trials, Real-world evidence.
- PairingCaution: TOP1 ADC immediately after TOP1 ADC
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, ADC sequencing, HR-positive / HER2-negative breast cancer.
- IdeaWatch routine care for drug combinations that quietly make cancer treatment worse
Shares Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.
- IdeaEmulate combination trials from real-world data to triage which ones to run
Shares Too many combinations to test, Weak real-world evidence and registries, Real-world evidence.
- IdeaLinked prescribing and outcome data to find drug interactions with cancer therapy
Shares Weak real-world evidence and registries, Real-world evidence.
- IdeaWearable activity data as a validated real-world endpoint
Shares Weak real-world evidence and registries, Real-world evidence.